局部晚期非小细胞肺癌个体化剂量处方:已发表正常组织并发症概率模型的验证
该研究对8个已发表的NTCP模型(≥2级急性食管炎AE2和放射性肺炎RP2)在241例接受化疗-IMRT的LA-NSCLC患者中进行了内部验证。最终AE2模型包含食管平均剂量和同步化疗(AUC=0.65,p<0.0001),最终RP2模型为稍作调整的版本,包含年龄、肺平均剂量和肺部合并症(AUC=0.73,p<0.0001)。这两个模型将用于LA-NSCLC患者个体化剂量处方的内部参考。
要点
- 241例LA-NSCLC患者中AE2发生率50%,RP2发生率12%。
- 最终AE2模型含食管平均剂量和同步化疗,AUC=0.65。
- 最终RP2模型含年龄、肺平均剂量和肺部合并症,AUC=0.73。
核心结论
- 8个已发表NTCP模型中,1个模型成功描述AE2,1个稍作调整的模型成功描述RP2。
- 这两个NTCP模型的预测值将作为LA-NSCLC患者个体化剂量处方的内部参考。
研究设计与样本
- 对8个已发表的候选NTCP模型(AE2和RP2)进行内部验证。
- 纳入241例2004至2014年间接受化疗-IMRT、剂量50-80 Gy@1.8-2.0 Gy的LA-NSCLC患者。
- 模型最终判定标准:显著预测AE2或RP2(p≤0.05)、具有区分度且校准良好(AUC>0.60;Hosmer-Lemeshow检验pHL>0.05),以1000次bootstrap样本的中位数评估。
主要发现
- AE2模型的区分度优于RP2模型(AUC=0.63-0.65 vs. 0.51-0.65)。
- 最终AE2模型包含食管平均剂量和同步化疗(AUC=0.65;p<0.0001)。
- 最终RP2模型为区分度最佳RP2模型的稍作调整版本,包含年龄、肺平均剂量和肺部合并症(AUC=0.73;p<0.0001)。
关键数值与推荐
- AE2和RP2发生率分别为50%和12%。
- 模型最终判定标准:p≤0.05、AUC>0.60、Hosmer-Lemeshow检验pHL>0.05。
- 最终AE2模型AUC=0.65,p<0.0001;最终RP2模型AUC=0.73,p<0.0001。
临床怎么用
- 在LA-NSCLC患者中,可参考最终AE2模型(食管平均剂量、同步化疗)和最终RP2模型(年龄、肺平均剂量、肺部合并症)的预测值进行个体化剂量处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify published normal tissue complication probability (NTCP) models suitable for patient-specific dose-prescription in locally advanced non-small cell lung cancer (LA-NSCLC) through in-house validation. MATERIAL AND METHODS: From eight previously published candidate NTCP models (≥grade 2 acute esophagitis and radiation pneumonitis; AE2, RP2), patient-specific dose-responses were calculated using model variables and fractionation-corrected doses for 241 LA-NSCLC patients treated with chemo-IMRT to 50-80 Gy@1.8-2.0 Gy between 2004 and 2014 (AE2/RP2 rate: 50%/12%). A model was judged final if it significantly predicted AE2 or RP2 (p ≤ 0.05), was discriminative and well calibrated (AUC > 0.60; Hosmer-Lemeshow test pHL > 0.05), which were assessed as the median over 1000 bootstrap samples. RESULTS: Models for AE2 had superior discrimination to RP2 models (AUC = 0.63-0.65 vs. 0.51-0.65). The final AE2 model included mean esophageal dose and concurrent chemotherapy (AUC = 0.65; p < 0.0001). The final RP2 model was a slightly adjusted version of the RP2 model with the best discrimination, and included age, mean lung dose, and pulmonary comorbidity (AUC = 0.73; p < 0.0001). CONCLUSION: Of the eight investigated and published NTCP models, one model successfully described AE2 and one slightly adjusted model successfully described RP2 in the independent cohort. Estimates from these two NTCP models will, therefore, be considered internally when prescribing patient-specific doses in LA-NSCLC patients.
引用
- Thor M, Deasy J, Iyer A, et al. Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models. Radiother Oncol. 2019. PMID: 31146070. doi:10.1016/j.radonc.2019.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。